BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx-February 2024-www.financetom.com

BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx

Mar 20, 2024 4:32 AM

March 20 (Reuters) - TELA Bio Inc ( TELA ):

* TELA BIO ANNOUNCES SALE OF DISTRIBUTION RIGHTS FOR WOUND

CARE

PRODUCT TO MIMEDX

* TELA BIO INC ( TELA ) - AS CONSIDERATION FOR SALE, MIMEDX WILL MAKE

INITIAL $5.0 MILLION PAYMENT

* TELA BIO ( TELA )- MIMEDX WILL MAKE FUTURE PAYMENTS BETWEEN

MINIMUM OF

$3.0 MILLION AND $7.0 MILLION BASED ON NET SALES OF NIVIS OVER

NEXT TWO YEARS

Source text for Eikon:

Further company coverage:

Previous page： Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing Next page： Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing

Jun 7, 2024

04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...

Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing

Jun 7, 2024

04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...

Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing

Jun 7, 2024

04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...

Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing

Jun 7, 2024

04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...